FluoSphera secured a pre-seed investment of USD 1M and completed a world-class acceleration program
Summary
FluoSpheras co-founders, Dr. Gregory Segala and Dr. Clelia Bourgoint, in the labs of IndieBio New York for the IBNY5 Demo Day. This investment allows FluoSphera to increase its R&D capacity to accelerate the generation of high-quality predictive data to discover the most promising candidate drugs.In 2023, FluoSphera will develop its unique technology platform to provide the pharma industry with unprecedented solutions to improve drug discovery. Gregory Segala said: Thanks to the amazing network of IndieBio, we discussed our development plans with outstanding mentors from the pharma industry. They helped us to refine our business and scientific strategy to position FluoSphera as a strong competitive provider of innovative solutions for drug discovery. IndieBio also tremendously increased the visibility of FluoSphera in the US where we could expand our network of partners, customers, and potential future investors.